Justin Klee (L) and Joshua Cohen (Amylyx)
Amylyx takes its ALS program to Nasdaq, raising the stakes for the biotech's only drug
The biotech that has gone all-in on ALS on its way to earning one of the highest neuroscience financing rounds in the last five years …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
